Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003088607 | SCV003485669 | uncertain significance | Symmetrical dyschromatosis of extremities; Aicardi-Goutieres syndrome 6 | 2023-01-15 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs749677748, gnomAD 0.004%). This sequence change replaces proline, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 434 of the ADAR protein (p.Pro434Ala). This variant has not been reported in the literature in individuals affected with ADAR-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ADAR protein function. |
Ambry Genetics | RCV004073273 | SCV004854571 | uncertain significance | Inborn genetic diseases | 2024-02-13 | criteria provided, single submitter | clinical testing | The c.1300C>G (p.P434A) alteration is located in exon 2 (coding exon 2) of the ADAR gene. This alteration results from a C to G substitution at nucleotide position 1300, causing the proline (P) at amino acid position 434 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |